Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone Combined With Methylprednisolone for Checkpoint Inhibitor-related Pneumonitis
NCT05280873Phase 1Unknown
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pirfenidone in pneumonitis (2 arms). Primary endpoints: Degradation time of Checkpoint Inhibitor-related Pneumonitis at 3 months and Proportion of degradation within three months at 3 months. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
pneumonitis
Beyond the preview
Go deeper on NCT05280873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280873.